BofA Merrill Lynch, Jefferies were joint bookrunning managers for deal
By Devika Patel
Knoxville, Tenn., Sept. 30 - Enzymotec Ltd.'s underwriters for the company's initial public offering of stock opted to exercise the deal's $9.27 million greenshoe in full for total proceeds of $71.03 million. The deal was announced Aug. 22 and priced for $61.77 million with the greenshoe on Sept. 26.
The company sold 5,073,800 ordinary shares at $14.00 per share. Of the shares, 661,800 were part of the fully exercised greenshoe.
BofA Merrill Lynch and Jefferies LLC were the joint bookrunning managers.
Settlement is expected Oct. 2.
Proceeds will be used for working capital requirements and other general corporate purposes.
The nutritional ingredients and medical foods company is based in Migdal Ha'Emeq, Israel. The company intends to list its common stock on the Nasdaq stock exchange under the symbol "ENZY."
| Issuer: | Enzymotec Ltd.
|
| Issue: | Ordinary stock
|
| Amount: | $71,033,200 (including $9,265,200 greenshoe)
|
| Shares: | 5,073,800
|
| Price: | $14.00
|
| Warrants: | No
|
| Bookrunners: | BofA Merrill Lynch and Jefferies LLC
|
| Lead manager: | Wells Fargo Securities, LLC
|
| Co-managers: | Canaccord Genuity and Wedbush Securities
|
| Announcement date: | Aug. 22
|
| Pricing date: | Sept. 26
|
| Settlement date: | Oct. 2
|
| Stock exchange: | Nasdaq: ENZY
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
